• 2025
    • 2025
      Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association
    • 2025
      Future development of arrhythmogenic risk scores in patients with heart failure and inherited dilated cardiomyopathy. A scientific statement of the Heart Failure Association of the ESC
    • 2025
      SGLT2 inhibitors for the prevention and treatment of heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the Heart Failure Association of India (HFAI)
    • 2025
      Management of aortic stenosis and chronic heart failure. A scientific statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC
    • 2025
      Heart failure with preserved ejection fraction in cancer patients and survivors. A Scientific Statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology